Interaction between protein kinase Cmu and the vanilloid receptor type 1 by Wang, Yun et al.
Interaction between Protein Kinase C and the
Vanilloid Receptor Type 1*
Received for publication, September 8, 2004
Published, JBC Papers in Press, October 7, 2004, DOI 10.1074/jbc.M410331200
Yun Wang‡§¶, Noemi Kedei‡, Min Wang§, Q. Jane Wang‡, Anna R. Huppler‡, Attila Toth‡,
Richard Tran‡, and Peter M. Blumberg‡**
From ‡NCI, National Institutes of Health, Bethesda, Maryland 20892-4255 and the §Neuroscience Research Institute,
Peking University, Beijing 100083, China
The capsaicin receptor VR1 is a polymodal nociceptor
activated by multiple stimuli. It has been reported that
protein kinase C plays a role in the sensitization of VR1.
Protein kinase D/PKC is a member of the protein ki-
nase D serine/threonine kinase family that exhibits
structural, enzymological, and regulatory features dis-
tinct from those of the PKCs, with which they are re-
lated. As part of our effort to optimize conditions for
evaluating VR1 pharmacology, we found that treatment
of Chinese hamster ovary (CHO) cells heterologously
expressing rat VR1 (CHO/rVR1) with butyrate enhanced
rVR1 expression and activity. The expression of PKC
and PKC1, but not of other PKC isoforms, was also
enhanced by butyrate treatment, suggesting the possi-
bility that these two isoforms might contribute to the
enhanced activity of rVR1. In support of this hypothesis,
we found the following. 1) Overexpression of PKC en-
hanced the response of rVR1 to capsaicin and low pH,
and expression of a dominant negative variant of PKC
reduced the response of rVR1. 2) Reduction of endoge-
nous PKC using antisense oligonucleotides decreased
the response of exogenous rVR1 expressed in CHO cells
as well as of endogenous rVR1 in dorsal root ganglion
neurons. 3) PKC localized to the plasma membrane
when overexpressed in CHO/rVR1 cells. 4) PKC di-
rectly bound to rVR1 expressed in CHO cells as well as to
endogenous rVR1 in dorsal root ganglia or to an N-ter-
minal fragment of rVR1, indicating a direct interaction
between PKC and rVR1. 5) PKC directly phosphoryl-
ated rVR1 or a longer N-terminal fragment (amino acids
1–118) of rVR1 but not a shorter one (amino acids 1–99).
6) Mutation of S116A in rVR1 blocked both the phospho-
rylation of rVR1 by PKC and the enhancement by
PKC of the rVR1 response to capsaicin. We conclude
that PKC functions as a direct modulator of rVR1.
The vanilloid receptor type 1 (VR1 or TRPV1)1 is a vanilloid-
gated, nonselective cation channel that belongs to the transient
receptor potential (TRP) channel superfamily. VR1 is ex-
pressed on small diameter neurons within sensory ganglia and
accounts for the highly selective action of vanilloids as excita-
tory agents for nociceptors. In addition to vanilloids, heat and
protons also influence vanilloid receptors and nociceptive path-
ways, and VR1 thus can be viewed as a molecular integrator of
chemical and physical stimuli that elicit pain (1). Following
tissue injury, the magnitude of VR1 responses is modulated by
the combined effects of protons, temperature, endogenous li-
gands, and signaling pathways, and this modulation of VR1
activity contributes to the sensitization of nociceptors associ-
ated with the development of allodynia and hyperalgesia (2).
Current evidence implicates multiple signaling pathways in
the modulation of VR1. PKA reduces vanilloid receptor type 1
(VR1) desensitization and directly phosphorylates VR1 (3).
PKC contributes to VR1 activation by pH (4), and PKC both
directly phosphorylates VR1 and is implicated in the develop-
ment of hyperalgesia (19). Finally, p38 mitogen-activated pro-
tein kinase activation increases the level of VR1 and maintains
hyperalgesia to heat (5).
PKD/PKC, PKD3/PKC, and PKD2 represent a class of
diacylglycerol-responsive protein kinases related to but distinct
from the PKCs. Features distinguishing the PKD/PKC family
members from the PKCs include a catalytic domain that is
distantly related to the calmodulin kinase domain while show-
ing little similarity to the highly conserved PKC catalytic do-
main, the presence of a pleckstrin homology domain, the lack of
a pseudosubstrate domain, and the lack of a C2 domain. In
addition, the tandem C1 domains, which account for the recog-
nition of diacylglycerol and the phorbol esters, are more widely
separated than in the PKCs (6).
The regulation of PKD/PKC is distinct from that of the
PKCs. In the case of the PKCs, binding of diacylglycerol/phor-
bol ester to the C1 domain induces a conformational change in
the enzyme, removing the pseudosubstrate inhibitory region
from the catalytic site and thereby activating the enzyme. In
addition, by completing the hydrophobic surface on the C1
domain, the bound diacylglycerol/phorbol ester drives the
membrane association of the PKC. The localization of the PKC,
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in turn, determines which of its possible substrates are acces-
sible for phosphorylation. In the case of PKD/PKC, the dia-
cylglycerol/phorbol ester has two distinct effects. First, the
diacylglycerol/phorbol ester activates the PKCs, which phos-
phorylate PKD/PKC and lead to its activation. This state of
activation of phosphorylated PKD is maintained during cell
disruption and immunoprecipitation, whereas for PKCs, their
in vitro activity remains dependent on the presence of lipid
cofactors (7). Second, by binding to the C1 domains of PKD/
PKC, the diacylglycerol/phorbol ester drives the membrane
association of the PKD/PKC (8).
Selective protein-protein interactions and phosphorylation of
unique downstream effectors are likely to form the basis of
isotype-specific functions. Each PKC family member shows an
optimal substrate consensus sequence. PKD/PKC, in particu-
lar, has substrate specificity very different from PKC isoforms.
These substrates include phosphatidylinositol kinases (9), 14-
3-3 proteins (10), the B-cell receptor complex (11), the tyrosine
kinase Syk (12), phospholipase C1 (11), Btk (Bruton’s tyrosine
kinase) (8), and a novel neuronal substrate of protein kinase D,
Kidins220 (kinase D-interacting substrate of 220 kDa) (13).
As part of our effort to optimize conditions for evaluating
VR1 pharmacology, we found that treatment with butyrate of
Chinese hamster ovary (CHO) cells heterologously expressing
VR1 (CHO/rVR1) enhanced rVR1 expression and activity. Bu-
tyrate is known to function as an inhibitor of histone deacetyl-
ase and affects the transcription of some genes. We found that
the expression of PKC and PKC1, but not other PKC iso-
forms, was also enhanced by butyrate treatment, raising the
possibility that these two isoforms might contribute to the
enhanced activity of rVR1. In support of this hypothesis, we
found that PKC directly bound to and phosphorylated rVR1.
Overexpression of PKC enhanced rVR1 activity, and reduced
expression of PKC by means of antisense oligonucleotides or
inhibition of its function through a dominant negative mutant
of PKC reduced rVR1 activity. We conclude that PKC func-
tions as a direct modulator of VR1.
EXPERIMENTAL PROCEDURES
Materials—[-33P]ATP (5000 Ci/mmol, 37 GBq  1 mCi) was ob-
tained from ICN (Irvine, CA), and phorbol 12-myristate 13-acetate
(PMA) was from LC Laboratories (Woburn, MA). Anti-capsaicin recep-
tor antibody was from Calbiochem. PKC (C-20) and PKC1 antibodies
were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Green
fluorescent protein (GFP) antibody was from Roche Applied Science.
GST antibody was from Amersham Biosciences. Cell culture reagents
and Lipofectamine were obtained from Invitrogen.
Preparation and Subculture of Cells Stably Expressing Rat VR1—
CHO cells stably transfected with rat VR1 in a pTet off regulatory
system were described previously (14). In this system, expression of the
rVR1 is repressed in the presence of tetracycline (1 g/ml) but is
induced upon removal of the antibiotic (14). For radioligand binding
experiments, cells were seeded in T75 cell culture flasks in the culture
medium with tetracycline (1 g/ml) and Geneticin (0.25 mg/ml). After 2
days, the culture medium was changed to medium without tetracycline,
and the cells were grown for an additional 48 h to induce rVR1 expres-
sion. The flasks were washed with PBS, and the cells were harvested in
PBS containing 5 mM EDTA. The cells were pelleted by gentle centrif-
ugation and stored at20 °C until assayed. For assay of 45Ca2 uptake,
cells were seeded into 24-well plates in medium with tetracycline (1
g/ml) and Geneticin (0.25 mg/ml). After 1 day, the culture medium was
changed to medium without tetracycline, and the cells were grown for
an additional 48 h to induce rVR1 expression. For calcium imaging,
cells were grown on round glass coverslips (25 mm).
DRG Neuron Isolation and Culture—2–3-Week-old male Sprague-
Dawley rats were provided by the Institute of Animal Research of the
Chinese Academy of Sciences. The experimental protocols were ap-
proved by the Animal Care and Use Committee of Peking University
Health Science Center. Rats were killed by decapitation under CO2
anesthesia. The spinal columns were removed aseptically, and dorsal
root ganglia from all levels were dissected out and collected in DMEM
containing 0.5% heat-inactivated fetal bovine serum (Invitrogen), 1 mM
sodium pyruvate, 25 mM HEPES, and penicillin/streptomycin (Invitro-
gen). Ganglia were digested with 1 mg/ml collagenase (Sigma) and
0.125 mg/ml trypsin (Sigma) for 30 min at 37 °C. Then fetal bovine
serum was added to terminate the digestion. The ganglia were tritu-
rated through a flame-polished Pasteur pipette to form a single cell
suspension. Cells were then washed three times with DMEM and
resuspended in the same medium, and the number of viable cells was
determined. Cells were plated in 10 g/ml polylysine-coated coverslips
and treated with 105 M cytosine arabinoside (Sigma) for 24 h. They
were then cultured for 2 days in DMEM containing 10% fetal bovine
serum, penicillin/streptomycin, and 200 ng/ml mouse submaxillary
gland 2.5S nerve growth factor (Sigma) before being used for
experiments.
45Ca2 Uptake—CHO/rVR1 cells or DRG neurons were incubated for
5 min at 37 °C in DMEM without serum, 0.25 mg/ml bovine serum
albumin, 0.2 Ci/well 45Ca2, and capsaicin as indicated. To determine
the heat dependence of 45Ca2 uptake, cells were incubated for 5 min at
44 °C in the medium specified above. To determine the pH dependence
of 45Ca2 uptake, cells were incubated for 5 min at 37 °C in the presence
of Dulbecco’s modified PBS with Ca2 and Mg2 (DPBS) supplemented
with 0.25 mg/ml bovine serum albumin, 0.2 Ci/well 45Ca2, and vari-
ous concentrations of the different compounds, adjusted to the indicated
pH with 1 M MES (Sigma). After incubation, cells were washed three
times with DPBS (with Ca2 and Mg2) and lysed in 400 l/well
radioimmune precipitation assay buffer (50 mM Tris-HCl, pH 7.5, 150
mM NaCl, 1% Triton X-100, 1% deoxycholate, 0.1% SDS) for 20 min.
Aliquots of the solubilized cell extracts were counted in a liquid scin-
tillation counter.
Imaging of Intracellular Calcium Levels ([Ca2]i)—CHO/rVR1 cells
or DRG neurons grown on coverslips were loaded with Fura-2/AM (10
M) (Molecular Probes, Inc., Eugene, OR) for 10 min at 37 °C and an
additional 50 min at room temperature (for CHO/rVR1 cells), washed,
and then incubated at room temperature for at least an additional 1 h.
For imaging, the coverslips were placed in a chamber at room temper-
ature. Images of Fura-2-loaded cells with the excitation wavelength
alternating between 340 and 380 nm were captured using a Cohu 4915
low light CCD camera on an InCyt Dual-wavelength Fluorescence Im-
aging and Photometry System (Intracellular Imaging Inc.). The ratio of
fluorescence intensity at the two wavelengths was calculated and plot-
ted as a function of time.
Treatment of Cells with Oligonucleotides—Phosphorothioate-modi-
fied oligonucleotides were purchased from Invitrogen. The antisense
sequence used was 5-GAC CGG AGG GGC GCT CAT-3 for PKC
based on the start codon (ATG) plus the 15 additional downstream
bases in the human PKC sequence. The sequences of sense and mis-
sense were 5-ATG AGC GCC CCT CCG GTC-3 and GCA GCA CAT
CGC ATC GAC-3, respectively (15). CHO/rVR1 cells or DRG neurons
were transfected with Lipofectamine 2000 as recommended by the
manufacturer with minor modifications. Briefly, for CHO/rVR1 cells, 1
day before transfection, 1  105 cells/well were plated into 24-well
plates in 0.5 ml of growth medium without antibiotics so that they were
30–50% confluent at the time of transfection. For transfection, the
oligonucleotide-Lipofectamine 2000 complexes were prepared as follows
(per well). 20 pmol of oligonucleotide was diluted in 50 l of Opti-
MEM® I reduced serum medium (Invitrogen) and gently mixed. Lipo-
fectamine 2000 (1 l) was added to 50 l of Opti-MEM® I medium and
mixed gently. After a 5-min incubation at room temperature, the di-
luted oligonucleotide was combined with the diluted Lipofectamine
2000, mixed, and incubated for 20 min at room temperature to allow the
oligonucleotide-Lipofectamine 2000 complexes to form. The 100 l of
oligonucleotide-Lipofectamine 2000 complex were then added to the
well and mixed gently by rocking the plate back and forth. Oligonucleo-
tide incubation medium was replaced every 12 h for 48 h. For DRG
neurons, isolated DRG neurons were seeded in 24-well plates at a
density of 1  105 cells/well. After 24 h of culture at 37 °C, the DRG
neurons were transfected with oligonucleotide following the same pro-
cedure as was used for the CHO/rVR1 cells.
Subcloning of PKC and Mutagenesis of PKC and rVR1—The hu-
man PKC cDNA cloned in pBluescript SK() vector was the kind gift
of Dr. K. Pfizenmaier (Institute of Cell Biology and Immunology, Uni-
versity of Stuttgart, Germany). To generate the GFP fusion construct,
PKC was amplified by PCR and subcloned into the XhoI-MluI site of
a pEGFP-N1 vector (Clontech) modified by inserting a MluI linker into
the plasmid digested with SmaI.
The kinase-inactive D727A PKC was prepared by mutating an
aspartic acid in the 727-position to an alanine in the pEGFP-N1-PKC
plasmid, and the GFPrVR1S116A was prepared by mutating a serine in
the 116-position to an alanine in the pEGFP-N3-rVR1 plasmid. Mu-
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tagenesis was performed with the QuikChangeTM site-directed mu-
tagenesis kit (Stratagene, La Jolla, CA).
The mutation was confirmed by sequencing performed by the DNA
minicore, Center for Cancer Research, NCI, National Institutes of
Health (Bethesda, MD).
Generation of Glutathione S-Transferase (GST)-rVR1 Fusion Pro-
tein—To generate N-terminal GST-tagged rVR1 (amino acids 1–838),
we have used the Gateway system (Invitrogen) following the manufac-
turer’s protocol. rVR1 was amplified by PCR from the pEGFP-N3-rVR1
plasmid (16) and subcloned into the pDONR201 and pDEST27 vectors.
The cytoplasmic N-terminal domains (amino acids 1–99, 1–118, and
1–432, respectively) and C-terminal domain (amino acids 686–838)
were obtained using the same procedure. The constructs were verified
by sequencing (sequence identical with AF-029310). The rat VR1-GST
fusion proteins were expressed in CHO cells using Lipofectamine Plus
reagent as recommended by the manufacturer (Invitrogen). 48 h after
transfection, the cells were washed three times with cold DPBS (Ca2-
and Mg2-free), harvested in PBS with proteinase inhibitor (proteinase
inhibitor tablet from Roche Applied Science), sonicated, and added to
the same volume of detergent mixture (50 mM Tris-HCl, pH 7.5, 150 mM
NaCl, 1% Triton X-100, 1% Nonidet P-40, 0.5% deoxycholate with
proteinase inhibitor and 2% (v/v) -mercaptoetanol). The mixture was
rotated at 4 °C for 2–3 h and centrifuged for 20 min at 15,000 rpm, and
the supernatant was added to glutathione-SepharoseTM 4 Fast Flow
beads (Amersham Biosciences). After being rotated overnight at 4 °C,
the beads were washed twice with 2 diluted detergent mixture (same
as above) containing -mercaptoethanol and then washed twice with
PBS containing -mercaptoethanol (0.1%, v/v). The fusion protein was
eluted with 10 mM reduced glutathione. The purity of the protein was
determined by SDS-polyacrylamide gel electrophoresis and staining
with Coomassie Brilliant Blue.
Western Blotting—Cells were harvested and lysed in a buffer con-
taining 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1.5 mM MgCl2, 10%
glycerol, 1% Triton X-100, 5 mM EGTA, 20 M leupeptin, 1 mM phenyl-
methylsulfonyl fluoride, 1 mM NaVO3, 10 mM NaF, and proteinase
inhibitor mixture. Equal amounts of protein (20 g) were subjected to
SDS-PAGE and electrotransferred to nitrocellulose membranes. Mem-
branes were blocked with 5% nonfat milk, 2% bovine serum albumin,
and 5% normal goat serum in Tris-buffered saline (TBS) for 1 h at room
temperature. Membranes were then probed with a primary antibody
against the specific protein, washed four times with 0.2% Tween 20 in
TBS, and then subjected to a second incubation with anti-mouse or
anti-rabbit secondary antibody conjugated to horseradish peroxidase
(1:1000; Bio-Rad). Bands were visualized by the ECL Western blotting
detection system (Amersham Biosciences). The primary antibodies
were polyclonal anti-capsaicin receptor antibody (1:100; Calbiochem), a
polyclonal anti-PKC (C-20) antibody (1:1000; Santa Cruz Biotechnol-
ogy), a monoclonal anti-GFP antibody (1:1000; Roche Applied Science),
and a monoclonal anti-GST antibody (1:1000; Amersham Biosciences).
In Vitro Binding—GST fusion proteins immobilized on glutathione-
Sepharose beads were incubated with 1 g of recombinant PKC (Cal-
biochem) in TBS buffer with 0.1% Triton X-100 for 5 h at 4 °C. Beads
were washed three times with incubation buffer, and bound proteins
were eluted in 30 l of SDS-PAGE sample buffer and processed for
4–20% Tricine SDS-polyacrylamide gradient gel electrophoresis. Sepa-
rated proteins were transferred and detected sequentially using a poly-
clonal anti-PKC antibody and a monoclonal anti-GST antibody on the
same blot. Horseradish peroxidase-conjugated secondary antibodies
and ECL (Amersham Biosciences) were used to visualize bands.
Co-immunoprecipitation between rVR1 and PKC in the rVR1 Het-
erologous Expression System—GFPrVR1 and GFP empty vector were
transfected into CHO cells individually using Lipofectamine Plus rea-
gent (Invitrogen). 48 h after transfection, cells were washed three times
with cold PBS and then lysed with 500 l of lysis buffer containing 50
FIG. 1. Effects of butyrate on the activity of rVR1 and the expression level of rVR1 and PKC. A, comparison of 45Ca2 uptake induced
by 300 nM capsaicin, pH (pH 5.5), and temperature (44 °C) in CHO/rVR1 cells treated with or without 10 M butyrate. The bars represent mean
values of quadruplicate determinations in single, representative experiments; error bars indicate S.E. B, the expression level of rVR1 and PKC
in CHO/rVR1 cells treated with or without 10 M butyrate as detected by Western blot. All experiments were repeated at least two additional times
with similar results. **, p  0.01 as compared with butyrate free group.
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mM Tris-HCl, pH 7.4, 150 mM NaCl, 1.5 mM MgCl2, 10% glycerol, 1%
Triton X-100, 5 mM EGTA, 20 M leupeptin, 1 mM phenylmethylsulfonyl
fluoride, 1 mM NaVO3, 10 mM NaF, and proteinase inhibitor mixture.
The lysates were centrifuged at 12,000 rpm at 4 °C for 15 min to remove
cellular debris. The supernatant was incubated with either 5 l of
anti-GFP (1:100) monoclonal antibody, or mouse control IGG at 4 °C
for 1 h. Protein A-Sepharose CL-4B resin (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA) was added to the samples, and the incubation
was continued for a further 3 h, after which samples were washed
three times with TBS, 0.1% Triton X-100. Separated proteins were
transferred and detected sequentially using a polyclonal anti-PKC
antibody and a monoclonal anti-GST antibody on the same blot.
Horseradish peroxidase-conjugated secondary antibodies and ECL
(Amersham Biosciences) were used to visualize bands. For multiple
detection with different antibodies, blots were first stripped in a
solution of 62.5 mM Tris-HCl, pH 7.5, 20 mM dithiothreitol, and 1%
SDS for 20–30 min at 50 °C and washed twice for 15 min with TBS,
0.1% Tween 20, followed by blocking and incubation with a new
primary antibody.
Co-immunoprecipitation between rVR1 and PKC in the Endogenous
DRG System—2–3-Week-old rats were killed by decapitation under CO2
anesthesia. The spinal columns were removed aseptically, and dorsal
root ganglia from all levels were dissected out and homogenized in lysis
buffer as above. After being rotated at 4 °C for 1 h, the lysates were
centrifuged at 12,000 rpm at 4 °C for 15 min to remove cellular debris.
The supernatant was incubated with either 5 l of anti-PKC (1:100)
polyclonal antibody or rabbit control IGG at 4 °C for 12 h. Protein
A-Sepharose CL-4B resin (Santa Cruz Biotechnology) was added to the
samples and the incubation was continued for a further 12 h, after
which samples were washed six times with TBS, 0.1% Triton X-100.
The subsequent steps were similar to those with the heterologous
rVR1 system.
Phosphorylation Reactions—Phosphorylation by PKC of rVR1 and
different N-terminal fragments was assessed following immunoprecipi-
tation. Cultured CHO cells were treated with 100 nM PMA or control
solvent (Me2SO; 0.1% (v/v) final concentration) for 20 min and then
washed three times with ice-cold PBS and lysed in 500 l of lysis buffer.
PKC was immunoprecipitated from cell lysates with PKC (C-20)
antibody (1:100) at 4 °C for 3 h. Immune complexes were recovered by
the addition of 50 l of Protein A-Sepharose (1 mg/ml; Santa Cruz
Biotechnology), and pellets were washed three times with lysis buffer
and three times with assay buffer (30 mM Tris-HCl (pH 7.5), 10 mM
MgCl2, and 1 mM dithiothreitol). The final pellet was resuspended in
assay buffer to yield a total volume of 40 l. To initiate the phos-
phorylation reaction, 10 l of phosphorylation mix (assay buffer
containing GSTrVR1 or the GSTrVR1 N-terminal fragments or GST
alone (10 g/ml) and 5 Ci of [-33P]ATP) was added. The mixture
was incubated at 30 °C for 20 min, and the reaction was terminated
by the addition of SDS-PAGE sample buffer. After boiling for 5 min,
the samples were subjected to SDS-PAGE. The gels were stained with
Coomassie Brilliant Blue, dried, and exposed to x-ray film for
autoradiography.
Visualization by Confocal Microscopy of GFPPKC Translocation—
Prior to observation, CHO/rVR1 cells were cultured on 40-mm round
coverslips in the culture medium with tetracycline (1 g/ml) and Gene-
ticin (0.25 mg/ml). 24 h later, GFPPKC was transiently transfected
into the cells with Lipofectamine Plus reagent as recommended by the
manufacturer (Invitrogen). After a 4-h incubation with the DNA and
Lipofectamine complex, the medium was replaced with CHO/rVR1-
inducing culture medium with Geneticin (0.25 mg/ml) without tetracy-
cline at 35 or 37 °C for a further 48 h. Before the measurement, the
coverslips were introduced into the microscope chamber system, which
was connected to a temperature controller set to 37 °C, and medium
was perfused through the chamber with a model P720 microperfusion
pump (Instech, Plymouth Meeting, PA). The images of the cells were
collected at 1-min intervals using LaserSharp software through a Bio-
Rad MRC 1024 confocal scan head mounted on a Nikon Optiphot
microscope with a 60 planapochromat lens. A krypton-argon gas laser
provided excitation at 488 nm with a 522/32 emission filter for green
fluorescence.
RESULTS
Butyrate, a Histone Deacetylase Inhibitor, Enhanced the Ac-
tivity of rVR1 and PKC Expression—Sodium butyrate is a
histone deacetylase inhibitor. Histone acetylation influences
the higher order structure of chromatin, resulting in a chroma-
tin conformation that is more accessible to transcription factors
and leading to enhanced transcription of some genes (17). As
part of our effort to optimize conditions for evaluating VR1
pharmacology, we have found that butyrate can influence the
function of VR1. Expression of rVR1 was induced in CHO/rVR1
FIG. 2. Effects of overexpression of PKC and dominant neg-
ative PKC on the activity of rVR1 as determined by 45Ca2
uptake. CHO/rVR1 cells were transfected with GFPPKC and domi-
nant negative GFPPKC (GFPDNPKC) for 48 h. The response of
CHO/rVR1 cells to 300 nM capsaicin or low pH (pH 5.5) was detected by
45Ca2 uptake. Overexpression of GFP empty vector and mock trans-
fection with vehicle alone were used as control. Bars, mean values of
quadruplicate determinations in single, representative experiments;
error bars, S.E. All experiments were repeated at least two additional
times with similar results. **, p  0.01 as compared with vehicle group.
FIG. 3. Effects of overexpression of PKC and dominant neg-
ative PKC on the activity of rVR1 as determined by calcium
imaging. A, CHO/rVR1 cells were transfected with GFPPKC or GFP
for 48 h; the response of CHO/rVR1 cells to 100 nM capsaicin was
detected by calcium imaging. B, CHO/rVR1 cells were transfected with
GFPPKC, GFP, or dominant negative GFPPKC (GFPDNPKC) for
48 h. The response of CHO/rVR1 cells to 100 nM capsaicin was detected
by calcium imaging. Overexpression of GFP empty vector and mock
transfection with vehicle alone were used as controls. Points represent
the averaged signal from a minimum of 16 cells imaged simultaneously.
The arrows indicate the start of the treatment. Each experiment was
repeated at least an additional two times with similar results on inde-
pendently cultured cells.
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cells by a change of medium to medium without tetracycline
either in the presence or absence of sodium butyrate (10 M).
The butyrate dramatically enhanced the functional activity of
rVR1 as evidenced by increased uptake of 45Ca2 in response to
capsaicin, low pH (pH 5.5), and high temperature (44 °C) (Fig.
1A). Likewise, the level of expression of rVR1 increased, as did
that of PKC (Fig. 1B) and PKC1 (data not shown); the level
of expression of other PKC isoforms was not changed. Because
of the reported effects of PKA and several PKC isoforms on
rVR1 activity (3, 4, 19), these observations suggested that the
increased activity of rVR1 in response to butyrate might reflect
not only the enhanced expression of the rVR1 protein itself but
also an effect of the elevated PKC and/or PKC1 on the
activity of rVR1.
Overexpression of PKC in CHO/rVR1 Cells Enhanced the
Activity of rVR1, and Expression of a Dominant Negative PKC
Mutant Attenuated the Activity of rVR1—To investigate the
possible role of PKC on the activity of rVR1, we overexpressed
GFPPKC in CHO/rVR1 cells. Overexpression of PKC en-
hanced the uptake of 45Ca2 in response to capsaicin (300 nM)
and low pH (pH 5.5) (Fig. 2). Conversely, when we expressed a
kinase-negative mutant of PKC, which would be expected to
function as a dominant negative, the dominant negative GFP-
PKC attenuated the response of rVR1 as detected by 45Ca2
uptake (Fig. 2), arguing that the endogenous PKC influenced
rVR1 function. We further evaluated the effects of overexpres-
sion of PKC or expression of the dominant negative PKC by
calcium imaging. As observed for 45Ca2 uptake, PKC over-
FIG. 4. Effects of PKC antisense ol-
igonucleotide on the activity of rVR1
in CHO/rVR1 cells. A, CHO/rVR1 cells
were treated with PKC antisense oligo-
nucleotides for 48 h; the response of CHO/
rVR1 cells to 100 nM capsaicin was deter-
mined by 45Ca2 uptake. Treatments with
vehicle or PKC sense or missense oligo-
nucleotides were used as controls. Bars,
mean values of quadruplicate determina-
tions in single, representative experi-
ments; error bars, S.E. Each experiment
was repeated at least an additional two
times with similar results on independ-
ently cultured cells. B, the expression
level of PKC in CHO/rVR1 cells treated
with antisense, sense, or missense as de-
termined by Western blot. Each experi-
ment was repeated at least an additional
two times with similar results on inde-
pendently cultured cells. **, p  0.01 as
compared with the sense group; ##, p 
0.01 as compared with the missense
group.
FIG. 5. Effects of PKC antisense ol-
igonucleotides on the activity of
rVR1 in primary cultured DRG neu-
rons. A, DRG neurons were treated with
PKC antisense oligonucleotides for 48 h;
the response of DRG neurons to 100 nM
capsaicin was determined by 45Ca2 up-
take. Bars, mean values of quadruplicate
determinations in single, representative
experiments; error bars, S.E. B, the ex-
pression level of PKC in DRG neurons
treated with antisense, sense, or missense
as determined by Western blot. Each ex-
periment was repeated at least an addi-
tional two times with similar results on
independently cultured cells. **, p  0.01
as compared with the sense group; ##, p
0.01 as compared with the missense
group.
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expression enhanced the elevation in internal calcium in re-
sponse to capsaicin, and the dominant negative mutant dimin-
ished the response (Fig. 3, A and B).
Pretreatment of PKC Antisense on CHO/rVR1 Cells or Pri-
mary Cultured DRG Neurons Inhibited the Response Induced
by Capsaicin—To further assess the effect of endogenous PKC
on VR1, we used antisense oligonucleotide to decrease endog-
enous PKC expression in CHO/rVR1 cells and then evaluated
the response of the cells to capsaicin (100 nM). Immunoblot
analysis confirmed that PKC expression was partially blocked
upon treatment with the specific antisense oligonucleotide (Fig.
4B); a little inhibition was observed upon treatment with sense
oligonucleotide, and no significant change occurred upon treat-
ment with missense oligonucleotide as compared with the
group treated with transfection reagents without oligonucleo-
tide. Functionally, preincubation of cells with specific antisense
for 48 h resulted in a 51.9  6.7% and a 55.5  8.2% decrease
in 45Ca2 uptake in response to capsaicin as compared with the
control groups of sense and missense oligonucleotide treat-
FIG. 6. The localization of GFPPKC in CHO/rVR1 and CHO
cells visualized by confocal microscopy. A, CHO cells were trans-
fected with GFPPKC and cultured at 37 °C for 48 h. B, CHO/rVR1
cells were transfected with GFPPKC and were then induced for VR1
expression by culturing in the absence of tetracycline at 37 °C for 48 h.
C, CHO/rVR1 cells were transfected with GFPPKC and were then
induced for VR1 expression by culturing in the absence of tetracycline
at 35 °C for 48 h. Localization of GFPPKC was visualized by confocal
microscopy. Each experiment was repeated at least an additional two
times with similar results on independently cultured cells.
FIG. 7. Co-immunoprecipitation of GFPrVR1 with PKC in
CHO cells. CHO cells were transfected with GFP empty vector or
GFPrVR1. After 48 h, the supernatants of cell lysates were immuno-
precipitated (IP) with anti-GFP antibody or IGG and collected by Pro-
tein A-Sepharose CL-4B resin; the immunocomplex was analyzed by
SDS-PAGE and sequential immunoblotting (IB) with anti-PKC anti-
body (A) and anti-GFP antibody (B). Each experiment was repeated at
least an additional two times with similar results on independently
cultured cells.
FIG. 8. Co-immunoprecipitation of endogenous rVR1 with
PKC in DRG neurons. The supernatants of rat DRG lysates were
immunoprecipitated (IP) with anti-PKC antibody or normal IGG as
control and collected by Protein A-Sepharose CL-4B resin; the immu-
nocomplex was analyzed by SDS-PAGE and sequential immunoblotting
(IB) with anti-VR1 antibody (A) and anti-PKC antibody (B). Each
experiment was repeated at least an additional two times with similar
results on independent samples.
FIG. 9. PKC bound directly to full-length rVR1 and the rVR1
N-terminal fragment in vitro. GST fusion proteins immobilized on
glutathione-Sepharose beads were incubated with recombinant PKC.
Bound proteins were eluted in SDS-PAGE sample buffer and processed
for 4–20% Tricine SDS-polyacrylamide gradient gel electrophoresis.
Separated proteins were sequentially detected using a polyclonal anti-
PKC antibody (A) and a monoclonal anti-GST antibody on the same
blot (B). Each experiment was repeated at least an additional two times
with similar results on independently cultured cells.
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ment, respectively. There was no detectable effect following
treatment with the sense or missense oligonucleotides as com-
pared with treatment with transfection reagents without oli-
gonucleotide (Fig. 4A).
To verify that the behavior of PKC as a modulator of rVR1
was not an artifact of the CHO/rVR1 heterologous expression
system, we also examined the effect of treatment of cultured rat
DRG neurons with the antisense oligonucleotide. As observed in
the case of the CHO/rVR1 cells, antisense treatment was able to
markedly reduce the level of PKC in DRG neurons compared
with controls treated with sense or missense oligonucleotides
(Fig. 5B). Likewise, 45Ca2 uptake by the cultured DRG neurons
in response to 100 nM capsaicin was significantly reduced by
treatment with the antisense oligonucleotide compared with con-
trol, sense, or missense oligonucleotide-treated cells (Fig. 5B).
GFPPKC Was Localized to the Cytoplasmic Membrane of
CHO/rVR1 Cells but Not of CHO Cells—To further understand
the interaction between PKC and rVR1, we examined the
localization of PKC in the cells. GFPPKC was transfected
into CHO/rVR1 cells, which were then induced for rVR1 ex-
pression by culturing in the absence of tetracycline at 37 °C for
48 h. Under these conditions, the GFPPKC localized to the
cytoplasmic membrane of the CHO/rVR1 cells (Fig. 6B). Inter-
estingly, in the CHO cells without rVR1, GFPPKC localized
predominantly to the cytoplasm (Fig. 6A). Since VR1 is a non-
selective cation channel and sensitive to high temperature, in
order to exclude a nonspecific effect of temperature, the CHO/
rVR1 cells transfected with GFPPKC were incubated at a
lower temperature, 35 °C, for comparison. Under these condi-
tions, likewise, GFPPKC localized to the cytoplasmic mem-
brane of the CHO/rVR1 cells (Fig. 6C). These results argue that
the presence of rVR1 influenced PKC localization, whether
directly or indirectly.
Direct Interaction between PKC and rVR1—The modula-
tion of the activity of rVR1 by PKC could be either direct or
indirect. Consistent with a direct interaction between rVR1
and PKC, in CHO cells expressing GFPrVR1, immunoprecipi-
tation of the rVR1 with monoclonal anti-GFP antibody co-
immunoprecipitated endogenous PKC (Fig. 7). Only back-
ground levels of PKC were immunoprecipitated in the CHO
cells expressing GFPrVR1 when control IGG was used or in
CHO cells expressing GFP alone upon immunoprecipitation
with monoclonal anti-GFP antibody.
A similar result was obtained using rat DRGs and antibodies
directed against rVR1 and PKC. We conclude that the inter-
action thus occurs at the endogenous levels of rVR1 and PKC
expression in the physiologically relevant context of the DRG
neuron; it is not simply an artifact of an engineered system
(Fig. 8).
In vitro binding experiments were performed to confirm the
direct interaction of PKC and rVR1. Fusion proteins between
GST and the full-length rVR1 or the N or C termini of rVR1
were immobilized on glutathione-Sepharose beads and incu-
bated with recombinant PKC; the bound proteins were then
analyzed by Western blotting. Both the full-length rVR1 and
the N terminus of rVR1 bound PKC, whereas the C-terminal
portion of rVR1 or GST alone did not (Fig. 9A). Controls con-
firmed (Fig. 9B) that similar amounts of the GST-full-length
rVR1, GSTrVR1 N-terminal fragment, and GSTrVR1 C-termi-
nal fragment bound to the beads. These experiments suggest
that PKC and rVR1 interact directly and that the interaction
depends on the presence of the N-terminal portion of rVR1.
FIG. 10. Phosphorylation by PKC of full-length rVR1 and different N-terminal fragments of rVR1. Cultured CHO cells were treated
with 100 nM PMA or control vehicle (Me2SO; final concentration 0.1% (v/v)) for 20 min. Cell lysates were prepared, and PKC was immunopre-
cipitated with anti-PKC(C-20) antibody (1:100). Immune complexes were recovered by protein A-Sepharose, washed, and resuspended in
phosphorylation assay buffer. To initiate the phosphorylation reaction, 10 l of phosphorylation mix (assay buffer containing GSTrVR1 or the
fusion protein between GST and the different N-terminal fragments or GST (10 g/ml) and 5 Ci of [-33P]ATP) was added. The mixture was
incubated at 30 °C for 20 min, and the reaction was terminated by the addition of SDS-PAGE sample buffer. After boiling for 5 min, the samples
were subjected to SDS-PAGE. Gels were then stained with Coomassie Blue (A), dried, and exposed to x-ray films for autoradiography (B). Each
experiment was repeated at least an additional two times with similar results on independently cultured cells.
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PKC Directly Phosphorylated Full-length rVR1 and N-ter-
minal Fragments of rVR1—Since PKC bound directly to rVR1
and its full-length N-terminal fragment, we asked whether
PKC could directly phosphorylate VR1 and its N-terminal
fragment. PKD/PKC is activated by phosphorylation through
a PKC-dependent pathway in all systems examined in vivo (7).
The increased activity of phosphorylated PKD is maintained
during cell disruption and immunoprecipitation. We therefore
used activated, immunoprecipitated PKC to evaluate rVR1
phosphorylation. PKC was incubated with GSTrVR1, with
the GSTrVR1 N-terminal fragment (residues 1–432) and with
the shorter GST-N-terminal fragments (residues 1–118 and
residues 1–99). We found that PKC was able to directly phos-
phorylate full-length rVR1, the full-length N-terminal frag-
ment of rVR1 (residues 1–432), and the N-terminal fragment
comprising the first 118 amino acids of rVR1 (Fig. 10B). It did
not, however, phosphorylate the N-terminal fragment com-
prising the first 99 amino acids, suggesting a possible phos-
phorylation site of PKC between amino acids 99 and 118. A
candidate phosphorylation site for PKC in this region is
serine 116.
Identification of Serine 116 of rVR1 as the Phosphorylation
Site for PKC—To confirm whether serine 116 indeed is a
site of regulation by PKC, wild type GFPrVR1 or a
GFPrVR1S116A mutant was cotransfected with GFPPKC
into CHO cells, and then the response of the cells to capsaicin
was evaluated by 45Ca2 uptake. For comparison, the effect
of the co-transfection with GFPPKC was compared with
that with GFP. Overexpression of GFPPKC increased
the response to capsaicin of wild type GFPrVR1 but not of the
GFPrVR1S116A mutant (p  0.01 as compared with the
GFPrVR1S116A plus GFPPKC group) (Fig. 11A). In addi-
tion, we also confirmed that PKC phosphorylated GSTrVR1
but not GSTrVR1S116A (Fig. 12). We conclude that serine
116 of rVR1 indeed is a functional target for PKC.
DISCUSSION
Our findings that PKC binds to, phosphorylates, and influ-
ences VR1 activity in response to capsaicin, heat, and pH
further emphasize the multiplicity of signaling pathways that
impact VR1 function. These pathways provide potential points
of intervention in the treatment of conditions involving VR1
function. The identification of PKC in particular further em-
phasizes the complex nature of VR1 regulation. PKC has
already been implicated in the development of thermal hyper-
algesia, as evidenced by a blunted response in mice in which
PKC has been knocked out (18). Furthermore, PKC has been
shown to directly phosphorylate VR1, providing a plausible
direct mechanism for the effect of PKC (19). It is known,
however, that PKC also phosphorylates and thereby activates
PKC (20). A second possible pathway for the PKC effects on
VR1 is therefore indirect, via PKC. Because PKC has a very
different kinase domain from the PKCs, as already discussed,
PKC provides a novel and distinct target for kinase inhibitors
targeted to influence VR1 function.
Our findings also have an important impact for understand-
ing the function of PKC. A growing number of proteins, such
as phosphatidylinositol kinases (9), 14-3-3 proteins (10), B-cell
receptor complexes (11), the tyrosine kinase Syk (12), phospho-
lipase C1 (11), Btk (8), and the two novel PKCs PKC and
PKC directly interact with PKC (21), but none of these
FIG. 11. Effect of overexpression of PKC on the activity of
wild type rVR1 and the rVR1S116A mutant as determined by
45Ca2 uptake. A, wild type GFPrVR1 or GFPrVR1S116A was co-
transfected with GFPPKC into CHO cells, and incubation continued
for 48 h. The response of the cells to 50 nM capsaicin was determined by
45Ca2 uptake. Co-expression with GFP empty vector and mock trans-
fection with vehicle alone were used as controls. Bars, mean values of
quadruplicate determinations in single, representative experiments;
error bars, S.E. B, the expression level of GFP, wild type GFPrVR1,
GFPrVR1S116A, and GFPPKC were determined by Western blot us-
ing anti-GFP antibody. Each experiment was repeated at least an
additional two times with similar results on independently cultured
cells. **, p 0.01 as compared with the no treatment group. ##, p 0.01
as compared with the GFPrVR1S116A plus GFPPKC group.
FIG. 12. PKC could not phosphorylate GSTrVR1S116A. Cul-
tured CHO cells were treated with 100 nM PMA or control vehicle
(Me2SO; final concentration 0.1% (v/v)) for 20 min. Cell lysates were
prepared, and PKC was immunoprecipitated with anti-PKC (C-20)
antibody (1:100). Immune complexes were recovered by protein
A-Sepharose, washed, and resuspended in phosphorylation assay
buffer. To initiate the phosphorylation reaction, 10 l of phosphoryla-
tion mix (assay buffer containing GSTrVR1 or GSTrVR1S116A (10
g/ml) and 5 Ci of [-33P]ATP) was added. The mixture was incubated
at 30 °C for 20 min, and the reaction was terminated by the addition of
SDS-PAGE sample buffer. After boiling for 5 min, the samples were
subjected to SDS-PAGE. Gels were then stained with Coomassie Blue
(A), dried, and exposed to x-ray films for autoradiography (B). Each
experiment was repeated at least an additional two times with similar
results on independently cultured cells.
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interacting proteins has been shown to be a PKC substrate.
An exception is Kidins220, which was isolated from PC12 cells,
interacts with PKD, and is directly phosphorylated by PKD
(13). Structural comparison of Kidins220 and VR1 reveals sim-
ilarities. Both are integral membrane proteins with N-terminal
segments of similar length containing ankyrin repeats and
with both the N-terminal and C-terminal domains in the cyto-
plasm. Our deletion results suggest a phosphorylation site in
the N-terminal domain of rVR1 between amino acids 99 and
118. PKC/PKD prefers peptide substrates with basic residues
upstream of the phosphorylation site serine, a hydrophobic
amino acid (Phe, Leu, or Val) at the 1-position, and a critical
Leu residue at the 5-position (22). Ser116 (sequence LY-
DRRSIF) represents such a consensus sequence. Finally, we
showed by site-directed mutagenesis that mutation of this res-
idue S116A blocks both the phosphorylation of rVR1 by PKC
and the enhancement by PKC of the response of rVR1 to
capsaicin (Figs. 11 and 12). Ser116 is also a major phosphoryl-
ation site in VR1 for PKA, and this site has been shown to be
involved in VR1 desensitization (3). Our results thus suggest
that PKC should likewise influence desensitization, with the
relative importance of PKA and PKC depending on the rela-
tive activity of these two pathways in a specific system. Our
results using the antisense construct to PKC in the rat DRG
neuronal cells suggest that the PKC pathway may have phys-
iological importance in these cells.
Histone deacetylase inhibitors are attracting interest as po-
tential therapeutics (23). Our findings imply that their possible
effects on C-fiber function through modulation of PKC expres-
sion should be carefully evaluated.
In this work, we identified PKC/PKD, a serine/threonine
kinase family member, as a modulator of vanilloid receptor
activity, directly associating with and phosphorylating it. Since
PKC regulates the response of VR1 to capsaicin and low pH,
it raised the possibility that VR1 may act as a PKC substrate
during inflammatory pain states and that PKC may be in-
volved in the development of chronic pain.
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